 triumph lung
messag merck bristol-my roch rhhbi present data
respect phase trial lung cancer yesterday chicago data
publish new england journal
medicin nejm follow announc result trial believ
merck emerg clear leader lung note hazard ratio
overal surviv merck even better bullish expect
result help solidifi merck posit leader front-lin nsclc cancer
follow present believ merck
emerg clear leader front-lin lung cancer set see page comparison
efficaci result three trial data immedi ad
keytruda label help propel keytruda sale near term
opinion may receiv fda approv lung set although
like take time approv receiv data present today seem
suffici matur result increas revenu estim keytruda
lung cancer decreas futur opdivo sale estim nsclc rais
price target see note lower pt see
note present present provid argument
discuss respect trial
find data present nejm quit tell curv keytruda
chemotherapi vs chemotherapi alon illustr almost immedi benefit contrast
curv opdivo yervoy vs chemotherapi demonstr chemotherapi
demonstr effect first month wane thereaft importantli effect
chemotherapi keytruda immedi almost immedi effect either
progression-fre surviv moreov overal surviv patient given keytruda top
chemotherapi contrast patient treat opdivo/yervoy
delay benefit high tmb versu chemotherapi alon month
data publish nejm monday late-break
session keytruda chemotherapi pemetrex platinum-bas drug
result significantli longer overal surviv os progression-fre surviv
chemotherapi alon metastat nonsquam nsclc patient without egfr
mutat surviv benefit associ keytruda chemotherapi cohort
observ subgroup regardless express determin tp tumor
proport score reduc risk death half vs chemotherapi alon
three subgroup includ neg pd-
hazard ratio better
expect help solidifi merck posit leader front-lin
nsclc cancer estim proport patient aliv month
keytruda chemotherapi cohort vs chemotherapi alon cohort
median os reach keytruda arm month chemotherapi
arm hr point median overal surviv may chang longer
follow-up data substanti censor kaplanmei curv around
time median reach
median month keytruda combin compar
month chemotherapi alon subgroup analysi
estim percentag patient
aliv progress diseas month keytruda
combin group vs chemotherapi alon overal respons rate orr
doubl keytruda chemotherapi chemotherapi alon
vs median durat respons month compar month
page analyst certif import disclosur
chemotherapi alon group improv respons rate occur
patient subgroup show largest benefit vs
expect safeti profil consist previou studi
believ data ad keytruda label immedi help
propel sale near term follow present
emerg clear leader front-lin lung cancer set
view import question studi remain whether addit keytruda
chemotherapi greater efficaci keytruda monotherapi evalu patient
discuss roy herbst md phd overal posit
present data point minim addit toxic combin arm
light efficaci believ hamper use keytruda combin
real world herbst point curv neg patient look
ident emphas os curv clearli separ patient popul
notion os trump nsclc high patient herbst said longer
follow-up data need make definit conclus comparison keytruda
monotherapi howev appeaer combin might benefici
like decis made individu patient accord herbst
conclus herbst state keytruda plu chemotherapi new soc non-
squamou nsclc would certainli agre furthermor herbst sate pd-
test continu roughli nsclc patient test statu
despit result regardless statu patient herbst also agre tmb
explor biomark treatment move earlier
patient see neoadjuv note nsclc discuss point
eleph room compar
exclus criteria differ driver mutant allowed/not allow egfr
crossov permitted/not permit symptomat excluded/includ howev
discuss made refer differ vs blockad believ
might biolog rational keytruda plu chemotherapi herald
new treatment paradigm rhhbi test seem
intern consist discuss state egfr/alk mutant might includ fals
posit need await os data draw final conclus comparison
two trial howev moment pole posit insigna ph
trial investig sequenti vs combin therapi nsclc keytruda
monotherapi combin vs chemotherapi combin treatment
data bmi also publish nejm monday morn
among patient high tumor mutat burden tmb mutat per
megabas significantli longer opdivo yervoy chemotherapi regardless
express rate tripl opdivo yervoy
vs chemotherapi vs regardless express squamous/
non-squam hr subgroup analys also provid combin vs
chemotherapi hr hr combin vs
chemotherapi squamou histolog hr non-squam histolog hr
median surviv month comparison month hr
also evalu opdivo vs chemotherapi pt tmb mut/mb
express secondari endpoint improv opdivo monotherapi
observ hr howev tmb high patient opdivo yervoy
show hr compar opdivo monotherapi
result demonstr near doubl overal respons rate orr
combin vs chemotherapi respond on-going
respons one year vs chemotherapi median durat respons
reach base earli descript analysi overal surviv os observ
combin versu chemotherapi patient high tmb hr safeti
profil consist previou studi
benefit opdivo yervoy significantli heighten patient high tmb
similar opdivo yervoy chemotherapi group among patient
low tmb mut/mb regardless express opdvio yervoy
group also show better efficaci result opdivo monotherapi high tmb patient
page analyst certif import disclosur
highlight import dual immun checkpoint blockad nsclc high tmb
phase trial continu evalu co-primari end point os
believ result could valid role opdivo yervoy effect treatment
regimen first-lin although believ fda approv set may take time
regardless one advantag io/io combin nsclc preserv
effect nsclc treatment chemotherapi howev remain seen
much share may abl garner front-lin lung cancer given data
also keytruda monotherapi success patient result
lower estim opdivo nsclc opdivo
discuss said tmb
dr naiyer rizvi columbia univers underlin notion tmb import
biomark may increas popular besid test sinc tmb
express correl seem opdivo plu yervoy might
adopt tmb high patient howev keytruda plu chemotherapi
also show strong result patient segment remain debat whether opdivo
plu yervoy would use tmb high high patient keytruda
monotherapi dr david limm harvard univers outlin questiont tmb
tmb interest robust/reproduc tmb test polymorph
mutat taken account distinct method determin tmb differ
result patient get analyz tmb furthermor
like hypermut includ would patient skew result
regardless dr limm state person commun dr hellman lead
investig tmb inde predict prognost
data present yet furthermor tmb associ os
dr limmel explain tumor high tmb higher propens achiev
resist put select treatment pressur term tmb vs test
cost amount biopsi favor test accord dr limmel
conclus dr limmel see potenti tmb need standard state
tmb readi use patient care
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic bristol-my
squibb compani merck co inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
buy describ stock expect provid total return price appreci plu yield within period
page analyst certif import disclosur
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
restrict describ issuer conjunct guggenheim secur llc engag certain transact compani polici applic
secur regul prohibit certain type commun includ invest recommend
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
equiti valuat risk valuat methodolog risk associ cover compani price target cover compani pleas
see recent company-specif research report http //guggenheimlibrari bluematrix com/client/librari jsp contact primari analyst
guggenheim secur llc repres email
prior guggenheim secur llc buy neutral sell rate definit follow rate definit chang
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within period
sell describ stock expect provid total neg return price appreci plu yield within period
